This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Immtech Pharmaceuticals, Inc.
Drug Names(s): DB289
Description: The aromatic diamidines represent a class of compounds with broad-spectrum antimicrobial activity; however, their development is hindered by a lack of understanding of their mechanism of antimicrobial action. DB75 is a trypanocidal aromatic diamidine that was originally developed as a structural analogue of the antitrypanosomal agent pentamidine. DB289 is a novel orally active prodrug of DB75. Recents studies suggest that DB75 inhibits mitochondrial function.
Deal Structure: Pafuramidine was initially synthesized at Georgia State University, a member of Immtech's Scientific Consortium.
Immtech has an agreement with Pharm-Eco Laboratories and the University of North Carolina at Chapel Hill, acting on behalf of a consortium of universities including UNC, Duke University, Auburn University and Georgia State University (the Consortium), regarding the continuing development and commercialization of the technology underlying the Company's dicationic pharmaceutical product candidates.
In April 2001, Johnson Matthey acquired Pharm Eco Laboratories.
Immtech and Par Pharmaceutical
In June 2007, Immtech granted an exclusive license to Par Pharmaceutical to commercialize pafuramidine maleate in the United States for the treatment of pneumocystis pneumonia (PCP) in AIDS patients. Immtech and Par may also collaborate on efforts to develop pafuramidine as a preventative therapy for patients at risk of developing PCP, including people living with...See full deal structure in Biomedtracker
Partners: Johnson Matthey Plc Endo International plc Onxeo SA
Pafuramidine maleate News
Additional information available to subscribers only: